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[57] ABSTRACT 
Anticonvulsant compositions comprise as the active 
ingredient a compound selected from the group consist 
ing of those of the formulae: 
wherein R1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 
2,6-dich1orophenyl, 4-pyridyl, 3-pyridyl, Z-pyridyl, or 
2-quinolyl, and R2 is hydrogen, m- or p-tri?uoromethyl, 
m-chloro-p-?uoro, p-methyl, p-ethyl, m- or p-chloro, 
m-nitro, p-bromo, p-tluoro, or p-COOR3, wherein R3 is 
lower alkyl of 1 to 4 carbon atoms. The compositions 
are administered to mammals in an amount to provide a 
dosage amount ranging from about 30 mg/kg to 300 
mg/kg. 
12 Claims, No Drawings 
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TRIAZOLINE ANTICONVULSANT COMPOUNDS 
AND COMPOSITIONS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a division of Ser. No. 629,554, ?led 
July 10, 1984, now US. Pat. No. 4,618,681, dated Oct. 
21, 1986, which in turn is a continuation-in-part of Ser. 
No. 476,792, ?led Mar. 18, 1983, now Us. Pat. No. 1° 
4,511,572, dated Apr. 16, 1985. 
TECHNICAL FIELD 
This invention relates to A2-1,2,3-triazolines and their 
use as a new and novel class of anticonvulsant drugs, 
and more particularly relates to certain additional new 
A2-1,2,3-triazolines, their methods of preparation, and 
compositions for their use in the treatment of convul 
sive disorders. 
BACKGROUND ART 
Studies over the past 15 years suggest that the pre 
vailing rate of epilepsy in the United States is between 5 
and 20 per 1000, and recent estimates drawn from popu 
lation surveys indicate that the higher rates are closer to 
the true prevalence. This means that 1 to 4 million 
Americans suffer from some form of epilepsy. For cer 
tain types of seizures there are no speci?c drugs avail 
able; for seizures that are controlled with currently 
available therapy, a new drug may allow a reduction in 
the toxic side effects. Despite these facts, between 1960 
and 1974, no new anticonvulsant drug was marketed in 
the United States (with the exception of diazepam, 
which was marketed primarily as a minor tranquilizer) 
(Vida, J. A. “Anticonvulsants,” Academic Press, New 
York, 1977). However, since the approval of carbamaz 
epine in 1974 and clonazepam in 1975, and sodium di 
propylacetate, eterobarb, mexiletine and others in 
1977-1978, there has been a resurgence of interest in the 
development of better anticonvulsant drugs for the 
management of epilepsy. Also responsible for this re 
newed interest is the establishment of the Anticonvul 
sant Screening Project of the Antiepileptic Drug De 
velopment (ADD) Program of NINCDS (National 
Institute of Neurological and Communicative Disorders 
and Stroke) of NIH, in January, 1975. 
In recent years hundreds of different heterocyclic 
compounds have been synthesized and screened for 
anticonvulsant activity. These include mostly ?ve and 
six membered ring systems containing up to three or 
four heteroatoms and seven membered ring systems 
related to the diazepines. Among the nitrogen contain 
ing heterocycles, a considerable amount of work has 
been done in the areas of ?ve membered rings bearing 
one or two nitrogen atoms. 
Five membered rings with 3 or 4 nitrogen atoms that 
have been investigated, include mostly, 1,2,4-triazoles 
and some tetrazoles. Very little has been done on 1,2,3 
triazoles (POPP, F. D., In “Anticonvulsants,” J. A. 
Vida, Ed. Academic Press, New York, 1977). The liter 
ature indicates that to date there are no references to 
any published work relating to studies on the anticon 
vulsant activity of triazolines. 
The 1,2,3-triazolines are a novel group of anticonvul 
sant compounds because their heterocyclic ring system 
is different from that of conventional anticonvulsant 
drugs. The presently marketed antiepileptic drugs, for 
the major part, have a dicarboximide function and/ or a 
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disubstituted quaternary carbon group (barbiturates, 
hydantoins, succinimides, oxazolidinediones) or closely 
related structure (primidone). On the other hand, the 
dicarboximide function, which contributes to the inher 
ent hypnotic and sedative activity of the barbiturates 
and related compounds, is absent in the triazolines. 
Triazolines including A2-1,2,3-triazolines, are known 
to some extent in the prior art, through applicant’s own 
publications of work in this area. None of the triazo 
lines, however, has been suggested heretofore for use as 
anticonvulsants. 
As indicated, the present applicant has published a 
number of papers involving her work on triazolines. 
The following publications discuss primarily the use of 
triazolines as intermediates in providing a route for the 
synthesis of certain anilinopyridazines and pyrazoles, 
(Kadaba, P. K., and Triplett, J. “Heterocycles, An In 
ternational Journal for Reviews and Communications in 
Heterocyclic Chemistry,” Vol. 9, No. 3, 1978, pp. 
243-246) and triazoles (Kadaba, P. K. “Syntheses, In 
ternational Journal of Methods in Synthetic Organic 
Chemistry,” No. 9: September, 1978, pp. 694-695.) 
The following publications describe the results of 
screening or evaluation of triazolines for pesticide and 
herbicide properties. (Kadaba, P. K., “Pestic. Sci.,” 
1974, 5, pp. 255-258.) (Kadaba, P. K., “Journal of Phar 
maceutical Sciences,” Vol. 59, No. 8, 1970, pp. 
1190-91.) 
The following publications primarily describe proce 
dures for the production of triazolines through cycload 
dition of diazomethane to Schiff bases and solvent ef 
fects on this reaction as well as steric effects. (Kadaba, 
P. K., and Edwards, J. “Journal of Organic Chemistry, 
26, 1961, pp. 2331-2335.) (Kadaba, P. K., “Tetrahedron, 
Vol. 22, 1966, pp. 2453-2460.) (Kadaba, P. K., and Fan 
nin, N., “Journal of Heterocyclic Chemistry,” 4, 1967, 
pp. 301-304.) (Kadaba, P. K., “Journal of Heterocyclic 
Chemistry, 6, 1969, pp. 587-589.) (Kadaba, P. K. “Tet 
rahedron, Vol. 25, 1969, pp. 3053-3066.) (Kadaba, P. 
K., “Synthesis, International Journal of Methods in 
Synthetic Organic Chemistry, No. 2: February, 1973, 
pp. 71-84.) (Kadaba, P. K., “Journal of Heterocyclic 
Chemistry, 12, 1975, pp. 143-146.) (Kadaba, P. K., 
“Journal of Heterocyclic Chemistry, 13, 1976, pp. 
1153-54.) 
In none of these publications, however, is there any 
disclosure of use of any of the 1,2,3 triazoline com 
pounds as anticonvulsants. 
SUMMARY OF THE INVENTION 
It is accordingly one object of the present invention 
to provide certain triazolines as anticonvulsant drugs. 
A further object of the present invention is to provide 
several new A2-1,2,3-triazolines and methods for their 
use in the treatment of convulsive disorders. 
A still further object of the present invention is to 
provide anticonvulsant compositions containing as the 
essential ingredient certain A2-1,2,3-triazo1ines and use 
of these triazolines as antiepileptic drugs in the treat 
ment of convulsive disorders such as epilepsy. 
Other objects and advantages of the present invention 
will become apparent as the description thereof pro 
ceeds. 
In satisfaction of the foregoing objects and advan 
tages, there is provided by this invention anticonvulsant 
compositions comprising as the active ingredient, a 
4,689,334 
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‘ compound selected from those of the following formu 
lae: 
Wherein R1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 
2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or 
Z-quinolyl, and R2 is hydrogen, m- or p-trifluoromethyl, 
p-methyl, m-chloro-p-fluoro-, p-ethyl, p-?uoro, m- or 
p-chloro, p-bromo, m-nitro, or p-COOR3, wherein R3 is 
lower alkyl of one to four carbon atoms. 
Also provided are methods for administration of the 
anticonvulsant compositions of this invention to mam 
mals in the treatment of convulsive disorders such as 
epilepsy including petit mal and grand mal. 
There is also provided by this invention certain new 
compounds which are useful as anticonvulsant.drugs. 
These compounds may be characterized by the follow 
ing general formulae: 
Wherein R1 is 4-pyridyl, S-pyridyl, 2-pyridyl, ortho 
chlorophenyl, 2,6-dichlorophenyl, or ortho-nitrophe 
nyl, and R2 is p-?uoro, p-bromo, m-chloro-p-?uoro, m 
or p-tri?uoromethyl, p-ethyl, m-chloro, or hydrogen. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
As indicated above, this invention relates to certain 
‘ 1,2,3-triazolines which are useful as anticonvulsants. 
The triazolines of this invention are to be named as 
A2-l,2,3-triazolines, or as lH-4,5-dihydro-l,2,3 
triazoles. The triazolines of this invention are substi 
tuted in the 1 and 5 positions by aryl or heterocyclic 
groups which may also contain substituents. The triazo 
line compounds of this invention have potent to moder 
ate anticonvulsant activity as antiepileptic drugs in the 
treatment of convulsive disorders such as petit mal 
(absence seizures) and grand mal (major motor sei 
zures). 
In one aspect of the invention, it relates to novel 
anticonvulsant compositions which comprise as the 
active ingredient a compound selected from those of the 
following formulae: 
N 
Wherein R1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 
2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, Z-pyridyl, or 
Z-quinolyl, and R2 is hydrogen, m- or p-tri?uoromethyl, 
p-methyl, m-chloro-p-?uoro, p-ethyl, p-fluoro, m- or 
p-chloro, p-bromo, m-nitro, or p-COORg, wherein R3 is 
lower alkyl of one to four carbon atoms. 
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In a further aspect of the present invention, new com 
pounds are provided which have anticonvulsant activ 
ity and which are of the following general formulae: 
In the above formulae, R1 is 2-pyridyl, 3-pyridyl, 
4-pyridyl, ortho-chlorophenyl, or ortho-nitrophenyl, 
and R2 is p-?uoro, m- or p-tri?uoromethyl, m-chloro-p 
?uoro, p-ethyl, or m-chloro, and when R1 =2,6 
dichlorophenyl, R2 can be p-bromo, and when R1=2 
pyridyl, R; can be hydrogen. 
There is further provided by this invention methods 
for administration of the anticonvulsant composition to 
mammals including animals and humans. 
The triazolines of this invention may be prepared by 
the reaction of diazomethane with Schiff bases as de 
scribed, for example, by Mustafa, A., (J. Chem. Soc.), 
234 (1949), and by Buckley, G. D., (J. Chem. 300.), 
1850, (1954). Further methods of preparation involving 
1,3-dipolar cycloaddition reactions are described in the 
applicants’ own publications in Kadaba, et al. (J. Org. 
Chem., 26, 2331 (1961), by Kadaba in “Tetrahedron,” 
22, 2453 (1966), by Kadaba in “Tetrahedron,” 25, 3053 
(1969) and J. Heterocyclic Chem., 12, 143, (1975). This 
reaction proceeds generally in accordance with the 
following equation. 
+ CH2N2 % 
R2 
R1 N 
l E 4N 
N 
A2-l,2,3-Triazolines 
In the above equation R1 and R2 are as de?ned above. 
Kinetic studies on solvent effects of this reaction 
indicate that protic solvents such as water have a gen 
eral accelerating effect on the reaction and by carrying 
out the addition reaction in an aqueous dioxane solution, 
high yields of triazolines are produced. 
As pointed out, the triazoline compounds and result 
ing anticonvulsant compositions of this invention are 
useful in the treatment of convulsive disorders. The 
potency of the compounds range from those which are 
very potent to those of moderate potency. A series of 
triazolines of this invention has been evaluated in Phase 
I anticonvulsant screening using two seizure models in 
the mouse, the maximal electro-shock seizure (MES) 
test and the subcutaneous pentylenetetrazole (Met 
razole) seizure threshold (scMet) test. These two meth 
ods of seizure provocation reliably elicit well character 
ized seizure phenomena (Chen. G., et al. Proc. Soc. 
Exp. Biol. Med., 87, 334 (1954), and together have been 
shown suf?cient to identify all compounds known to 
demonstrate anticonvulsant activity in other tests. 
Based on the Phase I screening results, the compound to 
4,689,334 
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be tested is placed in one of three categories. Those 
failing to demonstrate anticonvulsant activity at doses 
up to 300 mg/kg are considered inactive. Class 11 com 
pounds show anticonvulsant activity at doses greater 
than 100 mg/kg or show activity at 100 mg/kg which is 
not reinforced by similar activity at 300 mg/kg. Thus 
compounds of class or group II demonstrate anticon 
vulsant activity without signs of neurological de?cit, 
but do not have signi?cant potency. The Class I com 
pounds are those which are most promising as anticon 
vulsants. They demonstrate anticonvulsant activity in 
either the MES test or the ScMet test, or both at doses 
of 100 mg/kg or 30 mg/kg without signs of neurologi 
cal de?cit and thus have an estimated protective index 
of greater than I. 
The following table presents the results of these tests 
with respect to certain compounds of the present inven 
tion. This Table 1 identi?es the speci?c compounds 
tested, by chemical name and provides the anticonvul 
sant activity based on classi?cation in Group I or Group 
II. 
TABLE 1 
Anticonvulsant Activity 
Group Classi?cation 
ll 
Compound 
1. l-m-tri?uoromethylphenyl 
5-(o»chlorophenyl) 
A2~1,2,3-triazoline 
2. l-(p-Tri?uoromethylphenyl 
5-(o-chlorophenyl) 
A2»l,2,3-triazoline 
3. l-(p-EthylphenyD 
5-(o-chlorophenyl) 
A2-l,2,3-triazoline 
4. l-(m-Chlorophenyl) 
5-(o-nitrophenyl) 
A2-l,2,3-triazoline 
5. l-(m-Nitrophenyl) 
5-(2,4-dichlorophenyl) 
A2-l,2,3-triazoline 
6. l-(p-Bromophcnyl)» II 
5-(2,6-dichlorophenyl) 
A2-l,2,3-triazoline 
7. l-(Phenyl)- II 
5-(4-pyridyl) 
A2-l,2.3-triazoline 
8. l-(p-EthoxycarbonyD 
5~(4—pyridyl) 
A2-1,2,3-triazoline 
9. 1~(p-Chlorophenyl)- I 
5-(4-pyridyl) 
. l-(p-Fluorophenyl)- 1 I 
A2-l,2,3-triazoline 
l-(p-MethylphenyD 
A2-1,2,3-triazoline 
. l-(m-chlorophenyl) 
5-(4-pyridyD 
A2-l,2,3-triazoline 
. l-(phenyl) 
5-(2-pyridyl) 
A2-l,2,3-triazoline 
. l-(p-Chlorophenyl) 
5-(2-pyridyD 
A2-1,2,3-triazoline 
. l-(m-Nitrophenyl) 
5-(2-quinolyl) 
A2-l,2,3-triazoline 
A2-1,2,3-triazoline 
. l-(m-tri?uoromethylphenyl)- I 
5-(4-Pyridyl) 
A2-l,2,3-triazoline 
. 1—(m-chloro-p-fluorophenyl) 
5-(3-PyridyD 
II 
ll. 
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TABLE l-continued 
Anticonvulsant Activity 
Compound Group Classi?cation 
A2-l,2,3-triazoline 
As shown in the above table, the most potent com 
pounds are compounds 9,10,16 and 17 which are the 
four compounds of Class I. In addition, compounds 7 
and 12 in Class II are also effective anticonvulsant com 
pounds because they give 100% protection at 600 and 
300 mg/kg, respectively, without any signs of neurolog 
ical de?cit. Thus, these six compounds represent the 
preferred embodiments of the anticonvulsant composi 
tions of this invention. Compound 9 which is l-(para 
chlorophenyl)-5-(4-pyridyl)-A2-1,2,3-triazoline and 
compound 16 which is 1-(p-tri?uoromethylphenyl)-5 
(4-pyridyl)-A2-1,2,3-triazoline are the most preferred 
compounds of this invention. 
As indicated above while various preparative reac 
tions are known for the triazolines of the invention, the 
diazo-alkane-imine reaction of the following equation 1 
and the azide-ole?n cycloaddition reaction of the fol 
lowing equation 2 are generally preferred for 1,2,3 
triazoline synthesis: 
R] N l | 
R N 
N% 
Since Schiff bases (imines) bearing a range of aro 
matic or heterocyclic substitutents can be readily pre 
pared, the CHgNg-imine reaction is particularly suited 
for the synthesis of the l,5-substituted triazolines in this 
patent application. As pointed out above, this addition is 
preferably carried out in aqueous dioxane solutions 
according to the applicant’s previous publications. In a 
typical preparation, the Schiff base is dissolved in a 
cold, freshly prepared solution of CI-IZNZ in wet diox 
ane. The reaction mixture is then allowed to stand at 
l5°—20° C. for 2-4 days in the case of the reactive anils 
and 6-7 days in the case of the slow reactions. At the 
end of this period, the mixture is cooled and diluted 
with water to precipitate the triazoline adduct. 
The CHgNz for the reaction is prepared conveniently 
from N,N’-nitrosomethylurea in the same manner that 
undistilled ethereal solutions are obtained, but using 
1,4-dioxane in place of diethyl ether. Dioxane is the 
solvent of choice because of its easy miscibility with 
water and the ease with which it can be substituted for 
4,689,334 
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diethyl ether. The CHzNz solution thus obtained con 
tains water in suf?cient amounts to catalyze the reaction 
and is used immediately. 
The Schiff bases are prepared using standard proce 
dures by heating a mixture of the appropriate adehyde 
and amine in ethanol or alternatively by heating the 
mixture in benzene followed by azeotropic removal of 
the water, the latter being a more suitable procedure in 
difficult cases. 
The anticonvulsant compounds of the present inven 
tion may be administered to animals or humans at doses 
ranging from about 30 mg/kg up to about 300 mg/kg. 
Preferred levels of administration range from about 30 
mg/kg up to 100 mg/kg. The active ingredients or 
compounds of this invention may be administered in 
any desired form by injection or in the oral form. Con 
ventional adjuvents and carriers may be employed in 
combination with about 0.001 to 2.0 wt.% of the active 
ingredient. Thus the anticonvulsant compositions of this 
invention may be administered in pill form or by injec 
tion. As indicated above, the dosage rate ranges from 
about 30 mg/kg up to about 300 mg/kg. 
The following examples are presented to illustrate the 
invention but it is not to be considered as limited 
thereto. In the examples and throughout the speci?ca 
tion, parts are by weight unless otherwise indicated. 
EXAMPLE 1 
“_ Using the reaction of Equation 1 described above 
'fiinvolving cycloadditions of diazoalkanes to imines 
f‘(Schiff bases), the following compounds were prepared. 
“In the following Table 2, melting points and yields are 
given for new compounds prepared. 
TABLE 2 
Yield % 
77 
Compound M. pt. °C. 
49-51 1. l-m-tri?uoromethylphenyl 
5-(o-chlorophenyl) 
A2-l,2,3-triazoline 
2. l-(p-Tri?uoromethylphenyl) 
5-(o-chlorophenyl) 
A2-l,2,3-triazoline 
3. l-(p-Ethylphenyl) 
5-(o-chlorophenyl) 
A2-l,2,3-triazoline 
4. l~(m-Chloropheny1) 
5-(o-nitrophenyl) 
A2-1,2,3-triazoline 
5. l-(m-Nitrophenyl) 
5-(2,4-dichlorophenyl) 
A2-l,2,3-triazoline 
6. l-(p-Bromophenyl) 
5-(2,6—dichlorophenyl) 
A2-1,2,3-triazoline 
7. 1-(Phenyl) 
5-(4-pyridy1) 
A2-1,2,3-triazoline 
8. l-(p-Ethoxycarbony1) 
5-(4-pyridyl) 
A1-1,2,3-triazoline 
9. 1-(p-Ch1orophenyl) 
5-(4-PyridyD 
A2-l,2,3-triazoline 
. lv(p~Fluorophenyl) 
5-(4-pyridyl) 
A2=l,2,3-triazoline 
. l-(p-MethylphenyD 
5-(4-pyridyl) 
A2-l,2,3-triazoline 
. l-(m-chlorophenyD 
5-(4 pyridyl) 
A2-l,2,3-triazoline 
. 1-(phenyl) 
5-(2-pyridyl) 
A2-1,2,3-triazoline 
83-86 80 
48 
90-92 
156 75 
139-141 72 
109-110 80 
84-85 24 
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TABLE 2-continued 
M. pt. °C. Compound Yield % 
. l-(p-ChlorophenyD 
5-(2-pyridyl) 
A2-1,2,3-triazoline 
. l-(m-NitrophenyD 
5-(2-quinolyl) 
A2-l,2,3-triazoline 
. 1-(p-tri?uoromethylphenyD 
. l-(m-chloro-p-fluorophenyl) 
5-(3-pyridyl) 
A2-l,2,3-triazoline 
149-150 
68-71 42 
88-91 
These compounds were identi?ed through their ele 
mental analyses, characteristic melting point (they de 
compose at their melting point with vigorous evolution 
of nitrogen), and NMR spectra, which exhibits an ABC 
pattern in the 4.5 to 5.0 ppm region for the three protons 
at positions 4 and 5. 
These compounds were then evaluated in accordance 
with the methods set forth above for anticonvulsant 
characteristics. The results are set forth in Table 1 
above. As pointed out with respect to Table l, the com 
pounds demonstrate anticonvulsant activity in either 
the MES test or the scMet test or both. Compounds of 
Class I demonstrate this activity as doses of 100 mg/kg 
or 30 mg/kg without signs of neurological de?cit and 
thus have an estimated protective index of greater than 
1. 
EXAMPLE 2 
One of the compounds, compound 9 which is l-(para 
chloropheny1)-5-(4-pyridyl)A2-1,2,3-triazoline, was 
evaluated for further study to provide additional infor 
mation as to its general pro?le of anticonvulsant activ 
ity. 
Thirty minutes after administration, compound 9 of 
this invention exhibited anti-maximal electroshock 
(MES) activity at 300 mg/kg and anti-Metrazol activity 
at 100 mg/kg. Rotored toxicity was not seen in animals 
given up to 300 mg/kg of the test substance. Four hours 
after administration, the compound was ineffective by 
the MES test (although the tonic extension was slow) at 
300 mg/kg; however, anti-Metrazol activity was pres 
ent at this dose level. Thus, the pro?le of anticonvulsant 
activity of compound 9 was characterized by the ability 
to modify maximal electroshock seizure pattern and to 
elevate the Metrazol seizure threshold in nontoxic 
doses. Accordingly, the compound was subjected to 
Phase II Anticonvulsant Quanti?cation in Mice i.p., 
Phase III Toxicity Pro?le in Mice i.p., Phase IV Anti 
convulsant Quanti?cation in Mice p.o., Phase V Antiep 
ileptic Drug Differentiation in Mice i.p., and Phase VI 
Anticonvulsant Quanti?cation in Rats p.o. The results 
obtained provided the basis to compare the anticonvul 
sant activity and toxicity of compound 9 with those of 
clinically useful antiepileptic drugs. 
In this experiment male albino mice (CF No. 1 strain; 
18 to 25 g wt) obtained from Charles Rivers, Wilming 
ton, Mass, and male albino rats (Sprague Dawley, 100 
to 150 g wt) obtained from Simonsen, Gilroy, Calif., 
were used as experimental animals. All animals were 
allowed free access to both food (S/L Custom LaB 
4,689,334 
Diet-7) and water, except when they were removed 
from their cages for the experimental procedure. 
Compound :9 was compared with four prototype 
antiepileptic agents (phenytoin, phenobarbital, ethosux 
imide, and valproate). Compound 9 was administered in 
the requisite volume of 30% polyethylene glycol 400; 
whereas phenytoin, phenobarbital, ethosuximide, and 
valproate were administered in 0.9% sodium chloride 
solution. The drugs were administered either orally or 
intraperitoneally in a volume of 0.01 ml/ g body weight 
in mice and 0.04 ml/l0 g in rats. All tests were con 
ducted at the previously determined time of peak drug 
effect. To determine anticonvulsant potency and toxic 
ity, groups of at least eight mice or rats were tested with 
various doses of the drug until at least four points were 
established between the limits of 100% protection or 
toxicity and 0% protection or toxicity. The dose of drug 
required to produce the desired endpoint in 50% of 
animals (ED50) in each test, the dose eliciting evidence 
of minimal neurological toxicity in 50% of animals 
(TD50), the 95% con?dence interval, the slope of the 
regression line, and the SE. of the slope were then 
calculated by means of a computer program written by 
NINCDS. 
The pro?le of anticonvulsant activity for each sub 
stance was established by ?ve tests: one electrical and 
four chemical. The electrical test employed was the 
maximal electroshock seizure pattern test. This test 
measures the ability of the test drug to abolish the hind 
limb tonic-extensor component of maximal seizures 
induced in mice by 50 mA of current delivered for 0.2 
seconds or in rats at 150 mA of current delivered for 0.2 
seconds; this amount of current is approximately six 
times the threshold and reveals the ability of the test 
substance to prevent seizure spread. The four chemical 
tests include the subcutaneous Metrazol Seizure 
Threshold Test (sc Met Test), Subcutaneous Bicucul 
line Seizure Threshold Test (sc Bic Test), subcutaneous 
Picrotoxin Seizure Threshold Test (sc Pic Test), and the 
subcutaneous Strychnine Seizure Pattern Test (sc 
Strych Test). Except for the sc Strych Test, these tests 
measure the ability of anticonvulsants to afford com 
plete protection against threshold seizures induced by 
the subcutaneous injection of the CD97 of the convul 
sant agent. The $0 Strych Test measures the ability of 
the test substance to abolish all tonic components of 
seizures induced by the subcutaneous injection of the 
CD97 of strychnine. The sc CD97 of Metrazol, bicucul 
line, picrotoxin, and strychnine in mice is 85, 2.70, 3.15, 
and 1.20 mg/kg, respectively; the sc CD97 for Metrazol 
in rats is 70 mg/kg. 
The pro?le of toxicity for each test drug was estab 
lished by the following procedures: ?rstly, the minimal 
neurotoxic dose (T D50) was determined by the rotorod 
procedure at the time of peak neurotoxic effect. When a 
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normal mouse is placed on a knurled rod one inch in 
diameter rotating at a speed of six rpm it can maintain its 
equilibrium for long periods of time. Neurological de? 
cit is indicated by inability of the mouse to maintain its 
equilibrium for one minute in each of three trials on this 
rotating rod. Neurological de?cit in rats is indicated by 
ataxia, loss of placing response and muscle tone. Se 
condly, the overt signs and symptoms of toxicity in 
duced by each prototype agent and test substance were 
determined by giving two mice either 1TD50, 2TD50’s, 
or 4TD50’s and observing and testing them 10, 20, and 
30 minutes and 1, 2, 4, 6, 8, and 24 hours after drug 
administration for the onset, intensity, and type of overt 
toxicity. These observations also provide preliminary 
information essential for the subsequent determination 
of the HD50 and LDSO. The HD50 represents the me 
dian dose at which 50% of animals lose their righting 
re?ex. The 24-hour LD50 represents the median dose 
which causes death in 50% of the animals within 24 
hours. 
Except for bicuculline, all convulsant drugs (Metra 
zol, picrotoxin, and strychnine) administered to mice 
were dissolved in suf?cient 0.9% sodium chloride solu 
tion to make a concentration of 0.85%, 0.032%, and 
0.012%, respectively. Bicuculline was dissolved in 1 ml 
of warmed 0.1N HCl with the aid of a micro-mixer and 
suf?cient 0.9% sodium chloride solution added to make 
a 0.027% solution; the solution was used 15 to 45 min 
utes after preparation. Metrazol (3.5%) was adminis 
tered to rats in a solution of 0.9% sodium chloride. 
All convulsants were administered subcutaneously 
into a loose fold of skin on the back of the neck in a 
volume of 0.01 ml/ g body weight in mice; Metrazol was 
injected in a volume of 0.02 ml/ 10 g body weight in 
rats. The convulsant drugs were administered at the 
previously determined time of peak anticonvulsant ac 
tion of the drug under study. Except for picrotoxin 
treated animals, the mice (eight animals/group) were 
then observed for at least 30 minutes for the presence or 
absence of a seizure. The animals treated with picro 
toxin were observed for periods of 45 to 60 minutes for 
the presence or absence of a seizure. Except for strych 
nine, absence of a ?ve-second episode of clonic spasms 
(threshold seizure) was taken as protection. In the case 
of strychnine, complete abolition of the hindleg tonic 
extension was taken as protection. 
The results obtained in Phase II Anticonvulsant 
Quanti?cation studies in mice i.p., are shown in Table 3. 
It may be seen from the table that the times of peak 
effect (TPE) of the ?ve compounds range from 15 min 
utes to 6 hours; except for phenytoin (2 hours by all 
tests) and compound 9 by the rotorod test (6 hours), the 
TPE’s of the remaining substances vary from 15 min 
utes to one hour. 
TABLE 3 
PROFILE OF ANTICONVULSANT ACTIVITY OF 
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND 
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE 
Time Rotorod 
of Test TD50 ED50 m /k and P1 
Substance (hrs) (mg/ kg) MES sc Met 
4.40‘ 26.02‘ 
Compound 6,5} 1132.85 257.42 43.53 
9 (97045-133328) (23575-29753) (39.00-49.96) 
[7.92] [12.88] [8.75] 
6.89 <0.22 
Phenytoin 2,2,2 65.46 9.50 No Protection 
(52.49-72.11) (813-1044) up to 300 
4,689,334 
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PROFILE OF ANTICONVULSANT ACTIVITY OF 
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND 
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE 
Time Rotorod 
of Test TD50 EDSO (mg/kg! and P1 
Substance (hrs) (mg/kg) MES sc Met 
[15.23] [13.66] 
3.17 5.24 
Phenobarbital 5,1,1 69.01 21.78 13.17 
(62.84-72.89) (14.99-25.52) (5.87—15.93) 
[24.67] [14.98] [5.93] 
< 0.44 3.38 
Ethosuximide 5,54 440.83 No Protection 130.35 
(38309-48534) up to 1000 (110.99-15045) 
[18.37] [10.06] 
1.57 2.87 
valproate 5,5,5 425.84 271.66 148.59 
(36891-45040) (24697-33789) (12264-17702) 
[20.84] [12.83] [11.85] 
( ) 95% Con?dence interval 
[] Slope, regression line 
‘Protective Index (P1) = TDSO/EDSO 
3O 
35 
With respect to anticonvulsant activity, phenobarbital, 
the compound of this invention, and valproate had sig 
ni?cant anticonvulsant activity in nontoxic doses as 
. measured by both the maximal electroshock seizures 
(MES; EDSO’s 21.78, 257.42, and 271.66 mg/kg, respec 
tively) and subcutaneous Metrazol seizure (sc Met; 
EDSO’s 13.17, 43.53, and 148.59 mg/kg, respectively) 
tests. In contrast to the above, phenytoin had signi?cant 
anti-MES activity (ED50, 9.50 mg/kg) but did not pro 
tect against subcutaneous Metrazol seizures. Ethosuxi 
mide, on the other hand, was not able to protect against 
maximal electroshock seizures but had signi?cant anti 
Metrazol activity in nontoxic doses (ED50, 130.35 
mg/kg). 
With regard to minimal neurotoxicity, the compound 
of this invention was the least toxic (TD50, 1132.85 
mg/kg); however, 3 of 8 animals given 1300 mg/kg and 
5 of 8 animals given 1500 mg/kg were dead 24 hours 
after the administration of compound 9. Phenytoin and 
phenobarbital were the most toxic with TD50’s of 65.46 
and 69.01 mg/kg, respectively. Ethosuximide and val 
proate were equitoxic and induced minimal neurologi 
cal de?cit in 50% of mice at doses of 440.83 and 425.84 
mg/kg, respectively. 
It may also be seen from Table 3 that the protective 
indices (T D50/ED50=P.I.) by the MES test range 
from < 0.44 for ethosuximide to 6.89 for phenytoin. The 
P.I.’s of the remaining three compounds (compound 9 
of this invention, phenobarbital, and valproate) are 4.40, 
3.17, and 1.57, respectively. The P.I.’s of compounds 
50 
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active by the sc Met test range from 2.87 for valproate 
to 26.02 for the compound of this invention. Phenobar 
bital and ethosuximide were also effective by the sc Met 
test with P.I.’s of 5.24 and 3.38, respectively. 
Phase III, Toxicity Pro?le Studies in Mice given 
1TD50, 2TD50’s, and 4TD50’s of Compound 9 intra 
peritoneally, were also carried out on the compounds. 
The toxicity pro?le induced by Compound 9 was char 
acterized by decreased motor activity, ataxia, decreased 
respiration and cyanosis. In addition to these symptoms, 
one of two animals given 4TD50’s displayed rotorod 
toxicity. Both mice given 4TD50’s of Compound 9 
were dead 24 hours after drug administration. One of 
two animals given 2TD50’s was still ataxic and cyanotic 
at the end of 24 hours. A detailed qualitative description 
of the pro?le of acute toxicity in mice (i.p.) of Com 
pound 9 as well as phenytoin, phenobarbital, ethosuxi 
mide, and valproate is shown in Table 4. As shown in 
Table 4, the hypnotic dose 50 (HD50) and lethal dose 50 
(LDSO) of Compound 9 were 2050.56 and 2132.00 
mg/kg, respectively. Thus, the HD50 and LD50 for 
Compound 9 were signi?cantly higher than those for 
either phenobarbital (135.45 and 264.70 mg/kg, respec 
tively), phenytoin (178.34 and 229.61 mg/kg, respec 
tively), or valproate (885.33 and 1104.62 mg/kg, respec 
tively). The HD50 of Compound 9 was higher than that 
for ethosuximide (2050.56 vs 850.61 mg/kg), whereas 
the LD50’s were no signi?cantly different (2132.00 vs 
1752.23 mg/kg). 
Name 
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PROFILE OF ACUTE NEUROTOXICITY 
OF INTRAPERITONEALLY ADMINISTERED NO. 9 AND SOME PROTOTYPE 
ANTIEPILEPTIC DRUGS IN MICE 
l X TDSO 2 X TDSO 
Pro?le of Acute Toxicity, Mice i.p. 
Compound 9 
Phenytoin 
Phenobarbital 
Ethosuccimide 
Valproate 
‘24-hour period 
(1133 mg/kg) Both animals 
were ataxic beginning at 10 
min. One animal had decreased 
motor activity at 20 min and 
both had decreased motor 
activity and respiration with 
cyanosis at 2 hrs. Both 
appeared normal at 24 hrs. 
(65 mg/kg) Increased motor 
activity, slight ataxia, fre 
quent grooming, nervous be 
havior, and straub tail, 
animals were not toxic by the 
rotorod test. 
(70 mg/kg) Ataxia with 
increased motor 
activity followed 
by sedation and ptosis with 
one of two animals toxic by 
the rotorod test up to 4 hrs. 
(440 mg/kg) Uncoordinated 
motor activity, re?ex scratch 
ing, respiratory depression, 
ataxia. 
(400 mg/kg) Mild ataxia, with 
one of two mice toxic by the 
rotorod test. Appeared 
normal at the end of 4 hrs. 
(2266 mg/kg) Both 
animals were ataxic 
beginning at 10 min. 
They exhibited decreased 
respiration with 
cyanosis beginning at 
30 min and decreased motor 
activity beginning at 2 hrs. 
One animal appeared 
normal at 24 hrs 
while the other remained 
ataxic and cyanotic at 24 hrs. 
(130 mg/kg) Mild ataxia, 
periods of sedation, spasms of 
arching, rolling, straub tail, 
ptosis, and respiratory de 
pression. Later, spasms re 
duced and sedation increased. 
At 24 hrs, toxicity present, 
other symptoms less 
pronounced. 
(140 mg/kg) Ataxia with in 
creased motor activity follow 
ed by loss of righting re?ex, 
tremors, re?ex scratching, 
ptosis, sedation and some 
respiratory depression. Both 
mice regained their righting 
re?ex at 2 hrs and one of two 
was still toxic by the rotorod 
test at 8 hrs. 
(880 mg/kg) Uncoordinated 
motor activity, re?ex scratch 
ing, loss or’ righting re?ex 
at 4 mins but regained in 20 
mins, hypnosis followed at 
later time intervals by seda 
tion, ataxia, ptosis; vasodila 
tion and diarrhea. 
(800 mg/kg) Ataxia, with both 
animals toxic by the rotorod 
test, normal respiration and 
some sedation. Both animals 
appeared normal at 4 hrs. 
The anticonvulsant activity and minimal neurotoxic 
HD50 
LDSO' 
4 X TD50 (mg/kg) 
(4532 mg/kg) Both animals had 2050.56 
ataxia and decreased respira- (l59l.47—3228.68) 
tion beginning at 10 min. One [4.27] 
animal had decreased motor 213290 
activity and rotorod toxicity (166511436310) 
with cyanosis at 10 min. The [445] 
other animal had decreased 
motor activity at 2 hrs. Both 
animals were dead at 24 hrs. 
(260 mg/kg) Toxic manifesta- 178.34 
tions identical to 2 X TD50. At (15293-19545) 
1 hr, righting re?ex absent, [14.03] 
longer periods of sedation, 229m 
and spasms reduced to head (216_44_259_10) 
twisting and uncoordinated [15.39] 
movements; respiratory de 
pression continued, mice dead 
at 24 hours. 
(280 mg/kg) Ataxia with in- 135.45 
creased motor activity follow- (1 l4.90-l77.42) 
ed by loss of righting re?ex, [8.41] 
tremors, re?ex scratching, 264_7Q 
ptosis, sedation, anesthesia (2415543552) 
with analgesia and respiratory [15,95] 
depression. Both animals 
became cold to touch and 
cyanotic with increased res 
piratory depression; death 
occurred at approximately 3 
and 6 hrs. 
(1760 mg/kg) Uncoordinated 850.61 
motor activity, respiratory (75l.l9-917.93) 
depression, hypnosis and [16.43] 
anesthesia followed at later 175213 
time intervals by cyanosis (160102436664) 
and death at 24 hrs. [1435] 
(1600 mg/kg) Both 885.53 
animals died. (82086-95704) 
(At 3 X TDSO there was respira~ [12.46] 
tory depression, ptosis, hyp- 1104,62 
nosis but no analgesia. These 
animals were dead at 4 hrs.) 
(1021.54-1253.66) 
[11.41] 
dose (TDSO) upon oral administration were determined 
by Phase IV studies, Anticonvulsant Quanti?cation in 
Mice p.o. The TPE of Compound 9 after oral adminis 
tration was one-half hour by the anticonvulsant tests; 24 
hours was used as the TPE by the rotorod test. The 
TPE by the rotorod test was signi?cantly different from 
that obtained after intraperitoneal administration of test 
Compound 9 (24 hours and six hours, respectively). 
Except for valproate, the four prototype agents exhib 
ited TPE’s that were probably not signi?cantly differ 
ent from those observed after the intraperitoneal admin 
istration of these agents. Valproate had a TPE of one to 
two hours after oral administration vs one-fourth hour 
after intraperitoneal administration. 
With respect to anticonvulsant activity as measured 
by the MES test, phenytoin was again the most potent 
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(ED50, 9.04 mg/kg), Whereas valproate was the least 
potent (ED50, 664.80 mg/kg). Compared to phenytoin, 
phenobarbital was somewhat less potent by the MES 
test (ED50, 20.09 mg/kg). The test Compound 9, on the 
other hand, was l/ 15 and 1/32 as potent as phenobarbi 
tal and phenytoin, respectively, with an EDSO of 290.72 
mg/kg. When evaluated by the subcutaneous Metrazol 
threshold test after oral administration, phenobarbital 
was the most potent (ED50, 12.59 mg/kg) and valpro 
ate was the least potent (ED50, 388.31 mg/kg). The 
other two compounds (Compound 9 and ethosuximide) 
were equally potent by the scMet test with EDSO’s of 
152.56 and 192.71 mg/kg, respectively. 
By the oral route of administration in mice, cthosuxi 
mide and valproate were essentially equitoxic (T D50’s, 
4,689,334 
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879.21, and 1264.39 mg/kg, respectively). Phenytoin 
and phenobarbital were the most toxic with quite simi~ 
lar TDSO’s (86.71 and 96.78 mg/kg, respectively). Com 
pound 9 was somewhat more toxic than ethosuximide 
with a TD50 of 704.92 mg/kg; however, several deaths 
occurred within the dose-range selected for the rotorod 
regression line (600 and 800 mg/kg, 1 of 8 died; 700 and 
1000 mg/kg, 6 and 4 of 8 died). 
The R1. for Compound 9 is 2.42 by the MES test, 
whereas the P.I.’s for phenytoin, phenobarbital, etho 
suximide, and valproate are 9.59, 4.82, <0.44, and 1.90, 
respectively. The R1. for Compound 9 by the scMet 
test is 4.62; whereas those for phenytoin, phenobarbital, 
ethosuximide, and valproate are <0.29, 7.69, 4.56, and 
3.26, respectively. Thus, the R1. for the Compound 9 
substance by the MES test compares very favorably 
with the PI for valproate (2.42 and 1.90, respectively), 
whereas the R1. for Compound 9 by the scMet test 
(4.62) is higher than that for either ethosuximide (4.56) 
or valproate (3.26). 
The results obtained in Phase V evaluation, Antiepi 
leptic Drug Differentiation in Mice, indicated that the 
pro?le of anticonvulsant activity of Compound 9 is 
characterized by its effectiveness by the sc Bic and sc 
Met tests and its lesser effectiveness by the sc Pic test. 
Thus, its pro?le resembled that of phenobarbital and 
valproate to a certain extent; all three were effective 
against sc Met, sc Bio, and so Pic in nontoxic doses. In 
contrast to Compound 9 which was not effective 
-’ against sc Strych, phenobarbital and valproate were 
.il'effective against strychnine; valproate in nontoxic 
“doses, whereas phenobarbital had to be given in toxic 
‘doses in order to protect against this chemical convul 
sant. Phenytoin, on the other hand, was ineffective 
against Metrazol, bicuculline, and picrotoxin and was 
only capable of providing protection in 50% of animals 
"given strychnine. Ethosuximide was effective by the sc 
"Met, sc Bic, and so Pic tests, and only protected a maxi 
:i; mum of 62% of animals by the sc Strych test. However, 
"ethosuximide had to be given in toxic doses to protect 
against sc Bic seizures. It should also be noted that the 
"I. P.I.’s for Compound 9 against sc Met and sc Bic are ?ve 
and ?fty times higher, respectively, than those for phe 
nobarbital; the P.I. for Compound 9 by the sc Pic test 
compares favorably with those for phenobarbital, etho 
suximide, and valproate. 
In Phase VI studies, Anticonvulsant Quanti?cation in 
Rats p.o., it was found. that the TPE for Compound 9 in 
this species after oral administration was six hours by 
the toxicity, MES, and sc Met tests. The TPE of the 
other four compounds ranged from one-half hour for 
valproate to ?ve hours for phenobarbital. 
With respect to anticonvulsant activity, after oral 
administration in rats, phenobarbital was the most po 
tent by the MES test (ED50, 9.14 mg/kg), Whereas 
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Compound 9 and valproate were the least potent 
(EDSO’s, 265.76 and 489.54 mg/kg, respectively). The 
ED50 of phenytoin by this test was 29.82 mg/kg. When 
compared on the basis of the sc Met test, phenobarbital 
5 was the most potent (ED50, 11.55 mg/kg) and Com 
pound 9 and valproate were the least potent (EDSO’s, 
278.13 and 179.92 mg/kg, respectively). Ethosuximide 
was somewhat less potent than phenobarbital by this 
test with an ED50 of 53.97 mg/kg. 
With regard to neurotoxicity, phenobarbital was the 
most toxic (61.09 mg/kg) and ethosuximide and phenyt 
oin the least toxic (TDSO’s, 1012.31 and >3000 mg/kg, 
respectively). Valproate and Compound 9 were one 
?fth to one-sixth as toxic as phenobarbital with TDSO’s 
of 280.26 mg/kg and 393.74 mg/kg, respectively. 
In summary of the above results, for Compound 9 and 
the four prototype agents after intraperitoneal adminis 
tration in mice and oral administration in mice and rats, 
it may be stated that, in terms of the pro?le of anticon 
vulsant activity, Compound 9 is somewhat similar to 
that for phenobarbital and valproate. Unlike phenobar 
bital and valproate, Compound 9 is ineffective after i.p. 
administration in mice by the sc Strych test, whereas 
phenobarbital is effective in toxic doses and valproate is 
effective in nontoxic doses by this test. In terms of roto 
rod toxicity, Compound 9 is only one-third as toxic as 
ethosuximide and valproate in this species. After oral 
administration, Compound 9 is signi?cantly more neu 
rotoxic in rats than it is in mice; there is no signi?cant 
difference in the anticonvulsant potency of this sub 
stance by the MES and so Met tests in the two species. 
It should be noted that phenytoin administered orally in 
higher doses is absorbed only to a limited extent from 
the gastrointestinal tract of rats. Consequently, no mini 
mal neurotoxicity was observed in this species even in 
doses up to 3000 mg/kg. 
The quantitative toxicity pro?les after intraperitoneal 
administration of Compound 9 and the four prototype 
agents in mice are summarized in the following Table 5. 
It may be seen that the time of peak toxicity for Com 
pound 9 by the rotorod and righting re?ex tests are 6 
and 24 hours, respectively, whereas those for phenytoin 
are 2 and 12 hours, respectively. The TPE for the other 
three prototype agents by the rotorod and righting 
re?ex tests range from one-fourth to one hour. This 
table also shows that the LD50/HD50 and 
LDSO/I‘ D50 ratios for Compound 9 are 1.04 and 1.88, 
respectively. Thus, the ratios between either the mini 
mal toxic dose and the 24-hour lethal dose or the loss of 
righting re?ex dose and the 24-hour lethal dose for 
Compound 9 are lower than those for any of the four 
candidate substances; hence, it would appear that the 
margin between the minimal toxic dose and the 24-hour 
lethal dose is probably not satisfactory. 
TABLE 5 
QUANTITATIVE TOXICITY PROFILE OF 
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND 
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE 
Time 
of Test Dose 50 (mg/kg) 
Substance (hrs) Lethality Righting Re?ex Rotorod 
1.04‘ 1.88‘ 
Compound 9 24,24,6 2132.00 2050.56 1132.85 
(1666.1 1-3368. 10) (159l.47-3228.68) (97045-133328) 
[4.45] [4.27] [7.92] 
1.29 3.51 
Phenytoin 24,12,2 229.61 178.34 65.46 
(21644-25910) (15293-19545) (52.49-12.11) 
4,689,334 
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INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND 
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE 
Time 
of Test Dose 50 (mg/kg) 
Substance (hrs) Lethality Righting Re?ex Rotorod 
[15.89] [14.03] [15.23] 
1.95 3.84 
Phenobarbital 24,1,1 264.70 135.45 69.01 
(24155-28552) (11490-17742) (62.84-72.89) 
[15.95] [8.41] [24.67] 
2.06 3.98 
Ethosuximide 24%,; 1752.23 850.61 440.83 
(160702486664) (751.l9—917.93) (38309-48534) 
[14.75] [16.43] [18.37] 
1.25 2.59 
valproate 24,],1 1104.62 885.53 425.84 
(1021.54—1253.66) (82086-94704) (36891-45040) 
[11.41] [12.46] [20.84] 
( ) 95% Con?dence interval 
[ ] Slope, regression line 
‘Ratio LDSO/l-IDSO or LDSO/T D50 
‘In conducting these tests, it was noted that Com 
pound 9 is very insoluble and difficult to inject. Conse 
quently, it is necessary to administer the high doses 
required for the righting re?ex and 24-hour lethality 
tests in mice in double the volume. In view of this fact, 
additional studies were done to determine the effect of 
this double volume on the time of peak effect of the test 
substance. These studies indicated that the TPE may 
actually be between 12 and 20 hours. For example, after 
the intraperitoneal injection of 1132 mg/kg in mice, 2, 4, 
5, 4, and 3 of 8 animals were toxic by the rotorod test 6, 
12, 18, 20, and 24 hours, respectively, after administra 
tion of the test substance. Moreover, I, 3, and 4 of the 8 
mice were dead at 20, 40, and 46 hours, respectively. 
Examination of the peritoneal cavity of these animals 
revealed an unevacuated stomach that was approxi 
mately three times normal size; an empty, ?accid small 
intestine; and a vermiform appendix markedly enlarged 
from flatus. Rats given 400 mg/kg of the test substance 
either orally or intraperitoneally presented similar but 
somewhat milder gastrointestinal symptoms. This cur 
sory gross examination suggests there may be some 
relation between these gross abnormalities and the onset 
of toxic symptoms and death. Accordingly, additional 
pharmacokinetic and pharmacodynamic studies will be 
done in order to reveal mechanisms that may contribute 
to the long TPE for neurotoxicity and the abnormally 
low ratio between the minimal-toxic dose and the 24 
hour lethal dose. 
The effect of slope on the safety ratio (TD3/ED97) of 
Compound 9, phenobarbital and valproate indicates 
that after the intraperitoneal administration of nontoxic 
doses, the test substance (Compound 9) will protect 
97% of mice subjected to either the MES or sc MET 
test. After oral administration of the test substance in 
nontoxic doses, the same level of protection is obtained 
only in mice subjected to the MES test. In this regard, 
Compound 9 resembles phenobarbital more closely 
than it does valproate. Moreover, it should be noted 
that Compound 9 and the prototype agents used for 
comparison of the safety ratios do not provide 97% 
protection by the MES and so Met tests in nontoxic 
doses after oral administration in rats. I 
For a candidate drug to be useful in man, it should be 
adequately absorbed after oral administration. The ex 
tent of oral absorption can be determined from the ratio 
of the oral ED50/i.p. ED50, and should be equal to or 
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less than 4 for adequate absorption. In mice the oral 
TD50/i.p. TD50 and oral ED50/i.p. ED50 ratios for 
Compound 9 are 0.62, 1.13 and 3.50, by the rotorod, 
MES, and sc Met tests, respectively, which suggests 
that the test Compound 9 is adequately absorbed in mice 
after oral administration. 
For a candidate antiepileptic substance to be useful in 
the treatment of seizure disorders, its experimental pro 
file of action should compare favorably with that of 
clinically useful antiepileptic drugs. Such a comparison 
should include not only the anticonvulsant ef?cacy 
(ED50), but also the selectivity of toxic and anticonvul 
sant effects (slope of the dose-effect regression line), 
toxicity (LDSO, HDSO, and TDSO), protective indices 
(TDSO/EDSO), safety ratios (TD3/ED97), absorption 
characteristics (oral ED50/i.p. ED50 and oral 
TD50/i.p. TDSO) and the margin of safety (single dose 
?ve-day LD50/ED50). An analysis of the data for 
Compound 9, phenobarbital, ethosuximide, and valpro 
ate reveals that Compound 9 compares very favorably 
with the prototype agents. Moreover, the analysis also 
shows the relative merits and the disadvantages of 
Compound 9 compared to phenobarbital and valproate. 
The merits of the compound are the high P.I.’s derived 
from the sc Met and so Bic tests, the high safety ratios 
in mice (TD3/ED97; MES, 1.13; sc Met, 3.44) and the 
high 24-hour LDSO/EDSO safety ratio by the sc Met 
test. The disadvantages are related to a lack of selectiv 
ity (?at regression lines) by the 24-hour lethality and $0 
Pic tests and the unfavorable ratios (24-hour 
LDSO/HDSO and 24-hour LD50/T D50). 
The invention has been described herein with refer 
ence to certain preferred embodiments. However, as 
obvious variations thereon will become apparent to 
those skilled in the art, the invention is not to be consid 
ered as limited thereto. 
I claim: 
1. An anticonvulsant composition comprising as the 
active ingredient an anticonvulsive effective amount of 
a compound selected from the group consisting of those 
of the formulae: 
19 
N 
wherein R1 is o-chlorophenyl, o-nitrophenyl, 2, 4- or 
2,6-dichlorophenyl, or 2-quinolyl, and R2 is hydrogen, 
m- or p-trifluoromethyl, p—methyl, p-ethyl, m- or p 
chloro, m-nitro, p-bromo, p-?uoro or p-COOR3 
wherein R3 is lower alkyl or 1 to 4 carbon atoms, and a 
pharmaceutically acceptable carrier. 
2. A composition according to claim 1 wherein R1 is 
ortho-chlorophenyl and R2 is meta-tri?uoromethyl. 
3. A composition according to claim 1 wherein R1 is 
ortho-chlorophenyl and R2 is para-tri?uoromethyl. 
4. A composition according to claim 1 wherein R1 is 
ortho-chlorophenyl and R2 is para-ethyl. 
5. A composition according to claim 1 wherein R1 is 
ortho-nitrophenyl and R2 is meta-chloro. 
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6. A composition according to claim 1 wherein R1 is 
2,4-dichlorophenyl and R2 is meta-nitro. 
7. A composition according to claim 1 wherein R1 is 
2,6-dichlorophenyl and R2 is para-bromo. 
8. An anticonvulsant composition comprising, an 
anticonvulsant effective amount of the active ingredi 
ent, l-(m-chloro-p-?uorophenyl)-5-(3-pyridyl)-A2 
1,2,3-triazoline and a pharmaceutically acceptable car 
men 
9. A composition according to claim 8 wherein a 
sufficient amount of the active ingredient is contained in 
said composition to provide a dosage amount ranging 
from about 30 mg/kg to 300 mg/kg. 
10. A composition according to claim 1 wherein R1 is 
2-quinolyl and R2 is m-nitro. 
11. A method for the treatment of convulsive disor 
ders in mammals which comprises administration to a 
mammal of an effective dosage amount of a composition 
of claim 1. 
12. A method for the treatment of convulsive disor 
ders in mammals which comprises administration to a 
mammal of an effective dosage amount of a composition 
of claim 9. 
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